Carole Ho - Aug 20, 2024 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Signature
/s/ Tyler Nielsen, by power of attorney
Stock symbol
DNLI
Transactions as of
Aug 20, 2024
Transactions value $
-$549,928
Form type
4
Date filed
8/22/2024, 04:14 PM
Previous filing
Aug 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale -$58.4K -2.45K -1.74% $23.79 139K Aug 20, 2024 Direct F1, F2, F3
transaction DNLI Common Stock Sale -$344K -14.1K -10.16% $24.41 125K Aug 21, 2024 Direct F3, F4, F5
transaction DNLI Common Stock Sale -$147K -5.91K -4.74% $24.96 119K Aug 21, 2024 Direct F3, F4, F6
holding DNLI Common Stock 183K Aug 20, 2024 See footnote F7
holding DNLI Common Stock 25K Aug 20, 2024 See footnote F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.62 to $23.79 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Includes 118,810 Unvested RSUs.
F4 The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29,2023.
F5 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.84 to $24.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F6 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $24.84 to $25.21 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F7 The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
F8 The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.